Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche's Tecentriq Steals Lead In Triple-Negative Breast Cancer

Executive Summary

The PD-L1 inhibitor is the first checkpoint immunotherapy to gain approval in the tough-to-treat disease setting.

You may also be interested in...



Roche's Tecentriq Becomes Second In PD-1/L1 Family To Gain First-Line Lung Cancer Approval

The PD-L1 inhibitor's label excludes NSCLC patients with EGFR or ALK mutations, which could have been an advantage, but the indication largely reflects the registrational IMpower150 clinical trial's population.

Roche Remains Positive After Tecentriq Triple-Negative Breast Cancer Data

Clinicians and the company have heralded the IMpassion130 data presented at ESMO which showed that Roche's Tecentriq is the first immunotherapy to improve outcomes in TNBC but a slight blot on the landscape is that pretty much all of the survival benefit was seen in breast cancer patients with PD-L1 positive tumors.

Merck's Keytruda Offers Hope And Risk In Early Breast Cancer

I-SPY2 study shows promising efficacy for PD-1 inhibitor Keytruda in combination with chemo in high-risk breast cancer – including a tripling of response rate in triple-negative breast cancer – but also raises red flag on immune-mediated adverse events in early-stage patients.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124884

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel